» Articles » PMID: 28445310

Diagnostic Accuracy of Serum Alanine Aminotransferase As Biomarker for Nonalcoholic Fatty Liver Disease and Insulin Resistance in Healthy Subjects, Using 3T MR Spectroscopy

Overview
Specialty General Medicine
Date 2017 Apr 27
PMID 28445310
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Recognition of the close relationship of nonalcoholic fatty liver disease (NAFLD) with diabetes mellitus 2, obesity, metabolic syndrome, and cardiovascular disease has stimulated growing interest in NAFLD as a public health problem. Serum alanine aminotransferase (ALT) has been proposed as a marker of NAFLD, but levels are within the range currently considered "normal" in a large proportion of NAFLD subjects.The aim of the study was to determine the diagnostic accuracy of serum ALT for identifying individuals with NAFLD, using 3-Tesla (T) magnetic resonance spectroscopy (H-MRS).A cross-sectional study was conducted in 129 healthy subjects. Liver triglyceride content was quantified by H-MRS. NAFLD was defined as liver triglyceride content greater than 5.56%.Liver triglyceride content was >5.56% in 79 participants (NAFLD) and lower in the remaining 50 (normal). Serum ALT levels correlated positively with liver triglyceride content (r = 0.58, P < .001), Homeostatic Model Assessment for Insulin Resistance (r = 0.32, P < .01), and fasting insulin (r = 0.31, P < .01), and inversely correlated with adiponectin (r = 0.35, P < .01) and high-density lipoprotein cholesterol (r = 0.32, P < .01). Regression analysis showed that serum ALT was the best predictor of NAFLD (P < .01). Optimal serum ALT cut-off to predict NAFLD was 23 IU/L (area under receiver-operating characteristic curve: 0.93; sensitivity: 0.94; specificity: 0.72).This study shows that serum ALT is a sensitive and accurate biomarker of NAFLD if the "normal" ALT value is revised and established at a lower level. An ALT threshold of 23 IU/L identified 94% of individuals with NAFLD in the present series, using 3-T H-MRS for liver triglyceride quantification.

Citing Articles

ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.

Mannisto V, Salomaa V, Jula A, Lundqvist A, Mannisto S, Perola M JHEP Rep. 2024; 6(10):101172.

PMID: 39430577 PMC: 11489338. DOI: 10.1016/j.jhepr.2024.101172.


Possible protective effect of natural flavanone naringenin-reduced graphene oxide nanosheets on nonalcoholic fatty liver disease.

Abdelmoneim D, Eldomany E, El-Adl M, Farghali A, El-Sayed G, El-Sherbini E Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39414698 DOI: 10.1007/s00210-024-03495-9.


METS-IR, a Novel Simple Insulin Resistance Index, is Associated with NAFLD in Patients with Type 2 Diabetes Mellitus.

Ma X, Ji B, Du W, Shi S, Zhao H, Sheng J Diabetes Metab Syndr Obes. 2024; 17:3481-3490.

PMID: 39309308 PMC: 11416120. DOI: 10.2147/DMSO.S476398.


Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial.

Al-Baiaty F, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz D, Wan Md Zin W BMC Pediatr. 2024; 24(1):529.

PMID: 39160468 PMC: 11334366. DOI: 10.1186/s12887-024-04993-8.


Glycaemic Response to a Nut-Enriched Diet in Asian Chinese Adults with Normal or High Glycaemia: The Tū Ora RCT.

Sequeira-Bisson I, Lu L, Silvestre M, Plank L, Middleditch N, Acevedo-Fani A Nutrients. 2024; 16(13).

PMID: 38999851 PMC: 11243085. DOI: 10.3390/nu16132103.


References
1.
Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T . Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012; 47(6):696-703. DOI: 10.1007/s00535-012-0534-y. View

2.
Szczepaniak L, Nurenberg P, Leonard D, Browning J, Reingold J, Grundy S . Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2004; 288(2):E462-8. DOI: 10.1152/ajpendo.00064.2004. View

3.
Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin G . Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(8):1513-20.e1. DOI: 10.1016/j.cgh.2015.01.027. View

4.
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E . Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1):1-10. DOI: 10.7326/0003-4819-137-1-200207020-00006. View

5.
Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Rios C, Mendez-Sanchez N . In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. J Hepatol. 2010; 53(4):732-7. DOI: 10.1016/j.jhep.2010.04.018. View